Pfizer reveals updated trial results for Aromasin

Pfizer this week revealed that its breast cancer treatment Aromasin (exemestane tablets) has been shown to reduce the chances of the recurrence of the disease.

A trial conducted into the drug found that women who switched to Aromasin after two and a half years years of taking tamoxifen experienced a 19 per cent reduction in the risk of breast cancer recurrence.

This was compared to women who continued to take tamoxifen for a full five years of treatment.

Dr Stephen Jones, medical director of oncology research at Houston and Texas Oncology, stated: “Using breast cancer-free survival as an endpoint focuses on breast cancer events only, which is important in a population of older patients who are likely to have other medical problems.”

Last month, Pfizer and Bristol-Myers Squibb announced the submission of a regulatory approval request for the venous thromboembolism (VTE) drug apixaban in Europe.

The drug is set to be evaluated during the first half of 2010 for the prevention of VTE after orthopedic surgery.